Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Fifel, Karim ^a,b   Vezoli, Julien ^a,b   Dzahini, Kwamivi ^a,b   Claustrat, Bruno ^a,b   Leviel, Vincent ^a,b   Kennedy, Henry ^a,b   Procyk, Emmanuel ^a,b   Dkhissi Benyahya, Ouria ^a,b   Gronfier, Claude ^a,b   Cooper, Howard M ^a,b  

^a STEM CELL AND BRAIN RESEARCH INSTITUTE   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; HYDROCORTISONE; MELATONIN; SULPHATOXYMELATONIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSOCIATION; BRAIN DAMAGE; CIRCADIAN RHYTHM; CLOCK GENE; CONTROLLED STUDY; DARKNESS; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; GENE; HAPLORHINI; HORMONE RESPONSE; IN VIVO STUDY; LIGHT EXPOSURE; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIMATE; SLEEP DISORDER; SLEEP WAKING CYCLE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CIRCADIAN RHYTHM; DOPAMINE; FEMALE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACACA FASCICULARIS; MACACA MULATTA; MALE; MOTOR ACTIVITY; NEUROPEPTIDES; PARKINSONIAN DISORDERS; PHOTOPERIOD; RETINA; ROD OPSINS; SUPRACHIASMATIC NUCLEUS;

EID: 84899821147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086240     Document Type: Article

References (73)

1. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235-245. (Pubitemid 43238347)
2. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8: 464-474.
3. Carlsson A (1972) Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl 51: 11-42.
4. Arnulf I, Leu-Semenescu S (2009) Sleepiness in Parkinson's disease. Parkinsonism Relat Disord 15:S101-S104.
5. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E et al. (2001) Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21: 1787-1794. (Pubitemid 32184295)
6. Ueno T, Tomita J, Tanimoto H, Endo K, Ito K et al. (2012) Identification of a dopamine pathway that regulates sleep and arousal in Drosophila. Nat Neurosci 15: 1516-1523.
7. Castañeda TR, de Prado BM, Prieto D, Mora F (2004) Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J Pineal Res 36: 177-185. (Pubitemid 38429283)
8. Imbesi M, Yildiz S, Dirim Arslan A, Sharma R, Manev H et al. (2009) Dopamine receptor mediated regulation of neuronal "clock" gene expression. Neuroscience 158: 537-544.
9. Hood S, Cassidy P, Cossette MP, Weigl Y, Verwey M et al. (2010) Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci 42: 14046-14058.
10. Sleipness EP, Sorg BA, Jansen HT (2007) Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. Brain Res 1129: 34-42. (Pubitemid 46048774)
11. Hampp G, Ripperger JA, Houben T, Schmutz I, Blex C et al. (2008) Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood. Curr Biol 18: 678-683.
12. McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ et al. (2005) Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc Natl Acad Sci U S A 102: 9377-93781.
13. Gravotta L, Gavrila AM, Hood S, Amir S (2011) Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. J Mol Neurosci 45: 162-171.
14. Borbély AA (1982) A two process model of sleep regulation. Hum Neurobiol 1: 195-204.
15. Dijk DJ, Czeisler CA (1994) Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans. Neurosci Lett 17: 63-68.
16. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M et al. (2009) Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol 2: 574-582.
17. Vezoli J, Fifel K, Leviel V, Dehay C, Kennedy H et al. (2011) Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease. PLoS One 6, e23952.
18. Barcia C, Bautista V, Sánchez-Bahillo A, Fernández-Villalba E, Navarro-Ruis JM et al. (2003) Circadian Determinations of Cortisol, Prolactin and Melatonin in Chronic Methyl-Phenyl-Tetrahydropyridine-Treated Monkeys. Neuroendocrinology 78: 118-128. (Pubitemid 37188089)
19. Fertl E, Auff E, Doppelbauer A, Waldhauser F (1993) Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of L-dopa. J Neural Transm 5: 227-234. (Pubitemid 23227816)
20. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I (1997) Twenty-Four hour cortisol release profiles in patients with Alzheimer's and Parkinson's Disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging 18: 285-289. (Pubitemid 27360064)
21. Aziz NA, Pijl H, Frölich M, Roelfsema F, Roos RA (2011) Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease. J Neuroendocrinol 23: 519-524.
22. Mrosovsky N (1999) Masking: history, definitions, and measurement. Chronobiol Int 4: 415-429.
23. Redlin U, Cooper HM, Mrosovsky N (2003) Increased masking response to light after ablation of the visual cortex in mice. Brain Res 965: 1-8. (Pubitemid 36183679)
24. Emborg ME (2007) Nonhuman primate models of Parkinson's disease. ILAR J 48: 339-355.
25. Benazzouz A, Boraud T, Dubédat P, Boireau A, Stutzmann JM et al. (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284: 299-307.
26. Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE (1997) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 766: 107-112. (Pubitemid 27431440)
27. Dkhissi-Benyahya O, Gronfier C, De Vanssay W, Flamant F, Cooper HM (2007) Modeling the role of mid-wavelength cones in circadian responses to light. Neuron 53: 677-687.
28. Van Someren EJ, Kessler A, Mirmiran M, Swaab DF (1997) Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry 41: 955-963. (Pubitemid 27213706)
29. Emond P, Garreau L, Chalon S, Boazi M, Caillet M et al. (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy- 3beta-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbo- methoxy-3beta-(3′,4′-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 40: 1366-1372. (Pubitemid 27198083)
30. Poyot T, Condé F, Grégoire MC, Frouin V, Coulon C et al. (2001) Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa. J Cereb Blood Flow Metab 21: 782-792. (Pubitemid 32613532)
31. Shih MC, Hoexter MQ, Andrade LA, Bressan RA (2006) Parkinson's disease and dopamine transporter neuroimaging: a critical review. Sao Paulo Med J 124: 168-175. (Pubitemid 44420520)
32. Neumane S, Mounayar S, Jan C, Epinat J, Ballanger B et al. (2012) Effects of dopamine and serotonin antagonist injections into the striatopallidal complex of asymptomatic MPTP-treated monkeys. Neurobiol Dis 48: 27-39.
33. Bojkowski CJ, Arendt J, Shih MC, Markey SP (1987) Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin. Clin Chem 33: 1343-1348. (Pubitemid 18041967)
34. Aldhous ME, Arendt J (1988) Radioimmunoassay for 6-sulphatoxymelatonin in urine using an iodinated tracer. Ann Clin Biochem 25: 298-303.
35. Harthé C, Claustrat B, Brun J, Chazot G (1991) Direct radioimmunoassay of 6-sulfatoxymelatonin in plasma with use of an iodinated tracer. Clin Chem 37: 536-539. (Pubitemid 21892687)
36. Pääkkönen T, Mäkinen TM, Leppäluoto J, Vakkuri O, Rintamäki H et al. (2006) Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions. J Pineal Res 40: 110-115.
37. Dzahini K, Dentresangle C, Le Cavorsin M, Bertrand A, Detraz I et al. (2010) Presynaptic glutamate-induced activation of DA release in the striatum after partial nigral lesion. J Neurochem 113: 1459-1470.
38. Sokolove PG, Bushell WN (1978) The chi square periodogram: its utility for analysis of circadian rhythms. J Theor Biol 72: 131-160. (Pubitemid 8350595)
39. Almirall H, Bautista V, Sánchez-Bahillo A, Trinidad-Herrero M (2001) Ultradian and circadian body temperature and activity rhythms in chronic MPTP-treated monkeys. Neurophysiol Clin 3: 161-170. (Pubitemid 32661118)
40. Maetzler W, Liepelt I, Berg D (2009) Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 8: 1158-1171.
41. Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasić JR et al. (2008) VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 105: 78-90. (Pubitemid 351441627)
42. Stephan FK, Zucker I (1972) Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. Proc Natl Acad Sci USA 69: 1583-1586.
43. Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature 418: 935-941. (Pubitemid 34976023)
44. Aschoff J (1999) Masking and parametric effects of high-frequency light-dark cycles. Jpn J Physiol 49: 11-18.
45. Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130: 1586-1595. (Pubitemid 47355933)
46. Compta Y, Santamaria J, Ratti L, Tolosa E, Iranzo A et al. (2009) Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 132: 3308-3317.
47. Johnson CH, Elliott JA, Foster R (2003) Entrainment of Circadian Programs. Chronobiol Int 20: 741-774. (Pubitemid 37187518)
48. Liu AC, Lewis WG, Kay SA (2007) Mammalian circadian signaling networks and therapeutic targets. Nat Chem Biol 3: 630-639. (Pubitemid 47417711)
49. Fifel K, Dkhissi-Benyahya O, Cooper HM (2013) Lack of long term changes in circadian, locomotor and cognitive functions in acute and chronic MPTP mouse models of Parkinson's disease. Chronobiol Int 30: 741-755.
50. Rye D (2010) Seeing beyond one's nose: sleep disruption and excessive sleepiness accompany motor disability in the MPTP-treated primate. Exp Neurol 2: 179-180.
51. Tokura H, Aschoff J (1978) Circadian activity rhythms of the pig-tailed macaque, Macaca nemestrina, under constant illumination. Pflugers Arch 376: 241-243. (Pubitemid 8395340)
52. Masuda K, Zhdanova IV (2010) Intrinsic Activity Rhythms in Macaca mulatta: Their Entrainment to Light and Melatonin. J Biol Rhythms 25: 361-371.
53. Eidelberg E, Brooks BA, Morgan WW, Walden JG, Kokemoor RH (1986) Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 18: 817-822. (Pubitemid 16074928)
54. Mounayar S, Boulet S, Tandé D, Jan C, Pessiglione M et al. (2007) A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130: 2898-2914. (Pubitemid 350033961)
55. Hatfield CF, Herbert J, van Someren EJ, Hodges JR, Hastings MH (2004) Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia. Brain 127: 1061-1074. (Pubitemid 38623042)
56. Hnasko TS, Perez FA, Scouras AD, Stoll EA, Gale SD et al. (2006) Cre recombinase-mediated restoration of nigrostriatal dopamine in dopamine-deficient mice reverses hypophagia and bradykinesia. Proc Natl Acad Sci U S A 103: 8858-8863. (Pubitemid 43878108)
57. Nieoullon A, Cheramy A, Glowinski J (1977) Nigral and striatal dopamine release under sensory stimuli. Nature 269: 340-342. (Pubitemid 8178659)
58. Hirsh J, Riemensperger T, Coulom H, Iché M, Coupar J et al. (2010) Roles of dopamine in circadian rhythmicity and extreme light sensitivity of circadian entrainment. Curr Biol 20: 209-214.
59. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5: 677-687. (Pubitemid 44081890)
60. Meijer JH, Colwell CS, Rohling JH, Houben T, Michel S (2012) Dynamic neuronal network organization of the circadian clock and possible deterioration in disease. Prog Brain Res 199: 143-162.
61. Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ et al. (2008) Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 299: 2642-2655. (Pubitemid 351831594)
62. De Pedro-Cuesta J, Stawiarz L (1991) Parkinson's disease incidence: magnitude, comparability, time trends. Acta Neurol Scand 84: 382-388.
63. Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P et al. (2008) Prevalence and incidence of Parkinson's disease in The Faroe Islands. Acta Neurol Scand 118: 126-131.
64. Linder J, Stenlund H, Forsgren L (2010) Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Mov Disord 25: 341-348.
65. Willis GL, Moore C, Armstrong SM (2012) A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson's disease. Rev Neurosci 23: 199-226.
66. Forno LS, DeLanney LE, Irwin I, Langston JW (1993) Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv Neurol 60:600-608.
67. Jellinger KA. (1991) Pathology of Parkinson's disease changes other than the nigrostriatal pathways. Mol Chem Neuropathol 14:153-97.
68. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337-341. (Pubitemid 36314358)
69. Fulceri F, Biagioni F, Ferrucci M, Lazzeri G, Bartalucci A et al. (2007) Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res 1135:219-229. (Pubitemid 46176834)
70. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 84:5976-80. (Pubitemid 17135731)
71. Halliday G, Herrero MT, Murphy K, McCann H, Ros-Bernal F et al. (2009) No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov Disord 24:1519-1523.
72. Gaspar P, Febvret A, Colombo J (1993) Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Exp Brain Res 96:100-106. (Pubitemid 23332183)
73. Gomez-Gallego M, Fernandez-Villalba E, Fernandez-Barreiro A, Herrero MT (2007) Changes in the neuronal activity in the pedunculopontine nucleus in chronic MPTP-treated primates: an in situ hybridization study of cytochrome oxidase subunit I, choline acetyl transferase and substance P mRNA expression. J Neural Transm 114:319-326. (Pubitemid 46328652)